Want to see LQDA full AI Analyst Report?
LQDA Stock Chart & Stats
$70.49
$0.15(0.17%)
At close: 4:00 PM EDT
$70.49
$0.15(0.17%)
Day’s Range― - ―
52-Week Range$21.94 - $93.61
Previous CloseN/A
Volume722.63K
Average Volume (3M)5.10M
Market Cap
$3.25B
Enterprise Value$7.98B
Total Cash (Recent Filing)$284.18M
Total Debt (Recent Filing)$128.94M
Price to Earnings (P/E)24.8
Beta1.48
Next Earnings
Nov 10, 2026EPS Estimate
0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding89,508,890
10 Day Avg. Volume6,787,056
30 Day Avg. Volume5,098,073
Financial Highlights & Ratios
PEG Ratio0.83
Price to Book (P/B)66.33
Price to Sales (P/S)18.75
P/FCF Ratio-74.16
Enterprise Value/Market Cap2.45
Enterprise Value/Revenue17.70
Enterprise Value/Gross Profit19.15
Enterprise Value/Ebitda44.89
Forecast
1Y Price Target
$53.13Price Target Upside-24.63% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)2.09
Revenue Forecast (FY)$716.99M
Bulls Say, Bears Say
Bulls Say
Commercial TractionRapid sales growth and broadening patient and prescriber adoption indicate that YUTREPIA is gaining meaningful commercial traction. Continued uptake can support operating leverage, reinforce Liquidia’s position in inhaled prostacyclin therapies, and provide a durable base for future expansion.
Profitability And Cash BuildThe return to substantial profitability and positive cash generation materially strengthens Liquidia’s ability to fund commercialization, clinical development, and regulatory work internally. A larger cash balance also provides greater flexibility to support the pipeline and absorb operating investment.
Pipeline And Indication ExpansionFast Track designation and planned clinical development in Raynaud’s provide a pathway to broaden the treprostinil franchise beyond its current cardiopulmonary uses. Success could expand the addressable specialty market and diversify future revenue opportunities over time.
Bears Say
Settlement Cash OutflowsThe settlement creates substantial near- and medium-term cash outflows that will reduce financial flexibility even though management expects to fund them from sales and reserves. Payments may constrain the pace of reinvestment in commercialization, research, and pipeline development.
PH-ILD Indication LossRemoving the PH-ILD indication narrows YUTREPIA’s approved commercial scope and eliminates promotional access to a relevant patient population. This can limit the product’s long-term market opportunity and reduces the breadth of Liquidia’s current franchise.
Uneven Cash ConversionAlthough Liquidia is generating positive operating and free cash flow, relatively weak conversion from net income and sharply negative recent free-cash-flow growth indicate volatility beneath reported earnings. Sustained investment and settlement obligations make dependable cash generation especially important.
Liquidia Technologies News
LQDA FAQ
What was Liquidia Technologies Inc’s price range in the past 12 months?
Liquidia Technologies Inc lowest stock price was $21.94 and its highest was $93.61 in the past 12 months.
What is Liquidia Technologies Inc’s market cap?
Liquidia Technologies Inc’s market cap is $3.25B.
When is Liquidia Technologies Inc’s upcoming earnings report date?
Liquidia Technologies Inc’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were Liquidia Technologies Inc’s earnings last quarter?
Liquidia Technologies Inc released its earnings results on Aug 12, 2026. The company reported $0.74 earnings per share for the quarter, missing the consensus estimate of $0.743 by -$0.003.
Is Liquidia Technologies Inc overvalued?
According to Wall Street analysts Liquidia Technologies Inc’s price is currently Overvalued.
Does Liquidia Technologies Inc pay dividends?
Liquidia Technologies Inc does not currently pay dividends.
What is Liquidia Technologies Inc’s EPS estimate?
Liquidia Technologies Inc’s EPS estimate is 0.92.
How many shares outstanding does Liquidia Technologies Inc have?
Liquidia Technologies Inc has 89,508,890 shares outstanding.
What happened to Liquidia Technologies Inc’s price movement after its last earnings report?
Liquidia Technologies Inc reported an EPS of $0.74 in its last earnings report, missing expectations of $0.743. Following the earnings report the stock price went down -10.517%.
Which hedge fund is a major shareholder of Liquidia Technologies Inc?
Currently, no hedge funds are holding shares in LQDA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Liquidia Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.13 (-24.63% Downside)
$53.13 (-24.63% Downside)
Blogger Sentiment
Bullish
LQDA Sentiment 61%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 285.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $36.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 17.9%
Last 30 Days ▼ 17.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
77.66%
12-Months-Change
Fundamentals
Return on Equity
149.64%
Trailing 12-Months
Asset Growth
102.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Liquidia Technologies Inc
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
LQDA Company Deck
LQDA Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum—robust quarter-over-quarter sales (+31%), substantial patient adoption (~5,000+ patients started) and improving profitability (net income ~$74.7M, adjusted EBITDA ~$96.3M) alongside a healthy cash build (~$284M). Clinical data and a progressing pipeline (10 studies, L606 Phase III enrollment) underpin future growth potential. Offsetting factors include a 4x daily dosing requirement for the current product, planned increases in R&D and SG&A (R&D expected to double in H2 2026), pending patent litigation that could create legal/royalty risk, and the need for further community penetration. On balance, the positive operational, financial, and clinical developments materially outweigh the manageable near-term risks.View all LQDA earnings summariesLQDA Stock 12 Month Forecast
Average Price Target
$53.13
▼(-24.63% Downside)
Technical Analysis
Corcept Therapeutics
―
SCYNEXIS
―
Kiniksa Pharmaceuticals
―
Nasus Pharma Ltd.
―
Clinuvel Pharmaceuticals Limited Sponsored ADR
―
Ownership Overview
29.57% Insiders
8.40% Mutual Funds
0.41% Other Institutional Investors
40.63% Public Companies and
Individual Investors